skip to main content
Show Results with:

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

Parkhurst, Maria R et al.

Molecular therapy. Volume 19:Number 3 (2011, March); pp 620-626 -- Cell Press

Online access

  • Title:
    T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
  • Author: Parkhurst, Maria R;
    Yang, James C;
    Langan, Russell C;
    Dudley, Mark E;
    Nathan, Debbie-Ann N;
    Feldman, Steven A;
    Davis, Jeremy L;
    Morgan, Richard A;
    Merino, Maria J;
    Sherry, Richard M;
    Hughes, Marybeth S;
    Kammula, Udai S;
    Phan, Giao Q;
    Lim, Ramona M;
    Wank, Stephen A;
    Restifo, Nicholas P;
    Robbins, Paul F;
    Laurencot, Carolyn M;
    Rosenberg, Steven A
  • Found In: Molecular therapy. Volume 19:Number 3 (2011, March); pp 620-626
  • Journal Title: Molecular therapy
  • Subjects: Gene therapy--Periodicals; Molecular genetics--Periodicals; Dewey: 615.89505
  • Rights: Licensed
  • Publication Details: Cell Press
  • Abstract: Autologous T lymphocytes genetically engineered to express a murine T cell receptor (TCR) against human carcinoembryonic antigen (CEA) were administered to three patients with metastatic colorectal cancer refractory to standard treatments. All patients experienced profound decreases in serum CEA levels (74–99%), and one patient had an objective regression of cancer metastatic to the lung and liver. However, a severe transient inflammatory colitis that represented a dose limiting toxicity was induced in all three patients. This report represents the first example of objective regression of metastatic colorectal cancer mediated by adoptive T cell transfer and illustrates the successful use of a TCR, raised in human leukocyte antigen (HLA) transgenic mice, against a human tumor associated antigen. It also emphasizes the destructive power of small numbers of highly avid T cells and the limitations of using CEA as a target for cancer immunotherapy.
  • Identifier: System Number: ETOCvdc_100083517508.0x000001; Journal ISSN: 1525-0016; 10.1038/mt.2010.272
  • Publication Date: 2011
  • Physical Description: Electronic
  • Shelfmark(s): 5900.856500
  • UIN: ETOCvdc_100083517508.0x000001

Searching Remote Databases, Please Wait